Multiple Biologics for Multiple T2 Diseases: A Pharmacoepidemiological Algorithm for Sorting Out Patients by Indication

References

• Scadding GK, Scadding GW. Innate and adaptive immunity: ILC2 and Th2 cells in upper and lower airway allergic diseases. J Allergy Clin Immunol Pract. 2021;9:1851–1857.
   PubMed Web of Science ®Google Scholar
• Maspero J, Adir Y, Al-Ahmad M, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576–02021. doi:10.1183/23120541.00576-2021
   PubMedGoogle Scholar
• Brusselle GG, Koppelman GH, Taichman DB. Biologic therapies for severe asthma. Taichman DB, editor. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMra2032506
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149:1309–1317.e12.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi:10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi:10.1016/j.jaci.2020.05.032
   PubMed Web of Science ®Google Scholar
• Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:1141–1153.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi:10.1056/NEJMoa1314768
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252. doi:10.1056/NEJMoa1507247
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour J-P, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242–255. doi:10.1111/bjd.18898
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10:11–25. doi:10.1016/S2213-2600(21)00322-2
   PubMed Web of Science ®Google Scholar
• Taillé C, Chanez P, Devouassoux G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020;55:1.
   Web of Science ®Google Scholar
• Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A Study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10:2646–2656. doi:10.1016/j.jaip.2022.05.042
   PubMed Web of Science ®Google Scholar
• Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. doi:10.1111/cea.13614
   PubMed Web of Science ®Google Scholar
• Humbert M, Bourdin A, Taillé C, et al. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J. 2022;60:2103130.
   PubMed Web of Science ®Google Scholar
• Prada-Ramallal G, Takkouche B, Figueiras A. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol. 2019;19:53.
   PubMed Web of Science ®Google Scholar
• Larger E, Alexandre-Heymann L, Pilet S, Raoul T, Perray L, Maravic M. Polypharmacy in diabetes: a nation-wide, pharmacy-based, observational study. Diabetes Epidemiol Manag. 2022;8:100088. doi:10.1016/j.deman.2022.100088
   Google Scholar
• Joumaa H, Sigogne R, Maravic M, Perray L, Bourdin A, Roche N. Artificial intelligence to differentiate asthma from COPD in medico-administrative databases. BMC Pulm Med. 2022;22(1):357. doi:10.1186/s12890-022-02144-2
   PubMed Web of Science ®Google Scholar
• Vilcu A-M, Blanchon T, Sabatte L, et al. Cross-validation of an algorithm detecting acute gastroenteritis episodes from prescribed drug dispensing data in France: comparison with clinical data reported in a primary care surveillance system, winter seasons 2014/15 to 2016/17. BMC Med Res Methodol. 2019;19(1):110. doi:10.1186/s12874-019-0745-5
   PubMed Web of Science ®Google Scholar
• Panettieri RA, Ledford DK, Chipps BE, et al. Biologic use and outcomes among adults with severe asthma treated by US subspecialists. Ann Allergy Asthma Immunol. 2022;129:467–474.e3.
   PubMed Web of Science ®Google Scholar
• Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Eur Respir Rev. 2021;30(162):210067. doi:10.1183/16000617.0067-2021
   PubMed Web of Science ®Google Scholar
• Isaman D, Khan A, Lee S, et al. Oral corticosteroid burden and Healthcare Resource Utilization (HCRU) in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) undergoing Functional Endoscopic Sinonasal Surgery (FESS): a Real-World Retrospective Cohort Study. J Allergy Clin Immunol. 2023;151:AB201.
   Web of Science ®Google Scholar
• Heatley H, Tran TN, Bourdin A, et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. 2023;78(9):860–867. doi:10.1136/thorax-2022-219642
   PubMedGoogle Scholar
• Darmon D, Laforest L, Van Ganse E, Petrazzuoli F, Van Weel C, Letrilliart L. Prescription of antibiotics and anxiolytics/hypnotics to asthmatic patients in general practice: a cross-sectional study based on French and Italian prescribing data. BMC Fam Pract. 2015;16(1):14. doi:10.1186/s12875-015-0222-0
   PubMedGoogle Scholar
• Workman AD, Dattilo LW, Mitchell MB, Rathi VK, Bhattacharyya N. Rates of antidepressant, anxiolytic, and ADHD medication use among patients undergoing ESS. Ann Otol Rhinol Laryngol. 2023;000348942311790. doi:10.1177/00034894231179016
   Web of Science ®Google Scholar
• Bourdin A, Adcock I, Berger P, et al. How can we minimise the use of regular oral corticosteroids in asthma? Eur Respir Rev. 2020;29(155):190085. doi:10.1183/16000617.0085-2019
   PubMed Web of Science ®Google Scholar
• Vanderweil SG, Tsai C, Pelletier AJ, et al. Inappropriate use of antibiotics for acute asthma in United States emergency departments. Acad Emerg Med. 2008;15(8):736–743. doi:10.1111/j.1553-2712.2008.00167.x
   PubMed Web of Science ®Google Scholar